基于砹-211的放射性核素治疗：当前临床试验概况。
Astatine-211 based radionuclide therapy: Current clinical trial landscape.
作者信息
Albertsson Per, Bäck Tom, Bergmark Karin, Hallqvist Andreas, Johansson Mia, Aneheim Emma, Lindegren Sture, Timperanza Chiara, Smerud Knut, Palm Stig
机构信息
Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
出版信息
Front Med (Lausanne). 2023 Jan 6;9:1076210. doi: 10.3389/fmed.2022.1076210. eCollection 2022.
Abstract
Astatine-211 (At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.
摘要
砹 - 211（At）具有的物理性质使其成为基于α粒子的放射性核素治疗（也称为靶向α治疗，TAT）辐射源的最佳候选者之一。在此，我们总结已完成临床试验的主要结果，进一步描述正在进行的试验，并讨论未来前景。
相似文献
1
Astatine-211 based radionuclide therapy: Current clinical trial landscape.
Front Med (Lausanne). 2023 Jan 6;9:1076210. doi: 10.3389/fmed.2022.1076210. eCollection 2022.
2
Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.
Pharmaceutics. 2020 Dec 31;13(1):49. doi: 10.3390/pharmaceutics13010049.
3
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.
Expert Opin Biol Ther. 2016 Aug;16(8):1035-47. doi: 10.1080/14712598.2016.1185412. Epub 2016 May 19.
4
Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):192-217. doi: 10.1007/s00259-019-04475-5. Epub 2019 Aug 30.
5
Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.
Sci Rep. 2015 Jul 14;5:12025. doi: 10.1038/srep12025.
6
Targeted alpha therapy: part I.
Curr Radiopharm. 2011 Jul;4(3):176. doi: 10.2174/1874471011104030176.
7
Targeted cancer cell ablation in mice by an α-particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B.
Biochem Biophys Res Commun. 2018 Dec 2;506(4):1078-1084. doi: 10.1016/j.bbrc.2018.10.157. Epub 2018 Nov 5.
8
Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.
Med Phys. 2015 Jul;42(7):4094-105. doi: 10.1118/1.4921997.
9
The in vitro radiobiology of astatine-211 decay.
Radiat Res. 1986 Jan;105(1):27-36.
10
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
Curr Radiopharm. 2011 Oct;4(4):283-94. doi: 10.2174/1874471011104040283.
引用本文的文献
1
Biodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225/Francium-221 radionuclide generator Set-up.
Eur J Nucl Med Mol Imaging. 2025 Jul 1. doi: 10.1007/s00259-025-07427-4.
2
Copper-mediated radiochemistry: historical impact, current trends, and future possibilities.
Npj Imaging. 2025 Jun 10;3:25. doi: 10.1038/s44303-025-00087-x. eCollection 2025.
3
Locoregional radionuclide therapy of glioblastoma with [At]At-PDA-FAPI.
Sci Rep. 2025 May 25;15(1):18248. doi: 10.1038/s41598-025-03356-2.
4
Ortho-functionalization of a At-labeled aryl compound provides stabilization of the C-At bond against oxidative dehalogenation.
Sci Rep. 2025 May 15;15(1):16877. doi: 10.1038/s41598-025-01162-4.
5
Enhancing the Stability of At Radiopharmaceuticals: Insights from Ortho-Substituent Strategies.
ACS Med Chem Lett. 2025 Mar 20;16(4):504-507. doi: 10.1021/acsmedchemlett.5c00102. eCollection 2025 Apr 10.
6
Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care.
Cancers (Basel). 2025 Mar 31;17(7):1190. doi: 10.3390/cancers17071190.
7
The Advancement of Targeted Alpha Therapy and the Role of Click Chemistry Therein.
Molecules. 2025 Mar 13;30(6):1296. doi: 10.3390/molecules30061296.
8
Preclinical investigation of [Tb]Tb-DOTATATE and [Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy.
Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1383-1398. doi: 10.1007/s00259-024-07035-8. Epub 2025 Jan 2.
9
Enhancing the radionuclide theranostic concept through the radiohybrid approach.
RSC Med Chem. 2024 Nov 25. doi: 10.1039/d4md00591k.
10
Nanoscale Radiotheranostics for Cancer Treatment: From Bench to Bedside.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Sep-Oct;16(5):e2006. doi: 10.1002/wnan.2006.
本文引用的文献
1
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma.
Commun Biol. 2022 Nov 17;5(1):1260. doi: 10.1038/s42003-022-04209-8.
2
Pretargeting: A Path Forward for Radioimmunotherapy.
J Nucl Med. 2022 Sep;63(9):1302-1315. doi: 10.2967/jnumed.121.262186.
3
The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials.
Updates Surg. 2022 Dec;74(6):1805-1816. doi: 10.1007/s13304-022-01376-5. Epub 2022 Sep 18.
4
Targeting CD38 in Neoplasms and Non-Cancer Diseases.
Cancers (Basel). 2022 Aug 28;14(17):4169. doi: 10.3390/cancers14174169.
5
Targeted Alpha Therapy of Glioma Using At-Labeled Heterodimeric Peptide Targeting Both VEGFR and Integrins.
Mol Pharm. 2022 Sep 5;19(9):3206-3216. doi: 10.1021/acs.molpharmaceut.2c00349. Epub 2022 Aug 22.
6
Individualization of Radionuclide Therapies: Challenges and Prospects.
Cancers (Basel). 2022 Jul 14;14(14):3418. doi: 10.3390/cancers14143418.
7
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Clin Cancer Res. 2022 Sep 15;28(18):4146-4157. doi: 10.1158/1078-0432.CCR-22-0400.
8
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with At Intraperitoneal Radioimmunotherapy.
J Nucl Med. 2023 Jan;64(1):165-172. doi: 10.2967/jnumed.121.263349. Epub 2022 Jul 7.
9
Manual on the proper use of meta-[At] astato-benzylguanidine ([At] MABG) injections in clinical trials for targeted alpha therapy (1st edition).
Ann Nucl Med. 2022 Aug;36(8):695-709. doi: 10.1007/s12149-022-01765-1. Epub 2022 Jul 6.
10
Radiotheranostics in oncology: current challenges and emerging opportunities.
Nat Rev Clin Oncol. 2022 Aug;19(8):534-550. doi: 10.1038/s41571-022-00652-y. Epub 2022 Jun 20.
Zotero 插件